SAFETY AND EFFICACY OF INSULIN GLARGINE/LIXISENATIDE AND INSULIN DEGLUDEC/INSULIN ASPART IN TYPE 2 DIABETES PATIENTS NOT CONTROLLED ON BASAL INSULIN: A NETWORK META-ANALYSIS

被引：0
|
作者：
Jammah, A. [1 ]
机构：
[1] King Saud Univ, Dept Endocrinol, Riyadh, Saudi Arabia
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
394
引用
收藏
页码：A185 / A186
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
    Alhmoud, Eman N.
    Saad, Mohamed Omar
    Omar, Nabil Elhadi
    FRONTIERS IN ENDOCRINOLOGY, 2024, 14
  • [22] Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis
    Freemantle, Nick
    Chou, Engels
    Frois, Christian
    Zhuo, Daisy
    Lehmacher, Walter
    Vlajnic, Aleksandra
    Wang, Hongwei
    Chung, Hsing-wen
    Zhang, Quanwu
    Wu, Eric
    Gerrits, Charles
    BMJ OPEN, 2016, 6 (02):
  • [23] Duration and impact of hypoglycaemic events in patients with Type 2 diabetes treated with insulin degludec and insulin glargine: a meta-analysis
    Vora, J.
    Christensen, T.
    Kapur, R.
    Brod, M.
    DIABETIC MEDICINE, 2015, 32 : 67 - 67
  • [24] Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naive Patients with Type 2 Diabetes: A Randomized Controlled Trial
    Kumar, Ajay
    Franek, Edward
    Wise, Jonathan
    Niemeyer, Marcus
    Mersebach, Henriette
    Simo, Rafael
    PLOS ONE, 2016, 11 (10):
  • [25] Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Zhou, Wenchuan
    Tao, Jinxin
    Zhou, Xiaodong
    Chen, Hongxia
    DIABETES THERAPY, 2019, 10 (03) : 835 - 852
  • [26] Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Wenchuan Zhou
    Jinxin Tao
    Xiaodong Zhou
    Hongxia Chen
    Diabetes Therapy, 2019, 10 : 835 - 852
  • [27] Local tolerability of insulin degludec is comparable to insulin glargine: a meta-analysis of trials in type 1 and type 2 diabetes
    Meneghini, L. F.
    Schumm-Draeger, P. -M.
    Harris, S.
    Gall, M. -A.
    Lassota, N.
    Christiansen, J. S.
    DIABETOLOGIA, 2012, 55 : S380 - S380
  • [28] Comparison of Insulin Glargine with Insulin Degludec in Type 1 Diabetes Patients
    Kuroda, Akio
    Tsuruo, Miho
    Takeshi, Kondo
    Aki, Nanako
    Oguro, Yukari
    Endo, Itsuro
    Aihara, Ken-ichi
    Tamaki, Motoyuki
    Matsumoto, Toshio
    Matsuhisa, Munehide
    DIABETES, 2014, 63 : A232 - A232
  • [29] Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
    Charbonnel, Bernard
    Bertolini, Monica
    Tinahones, Francisco J.
    Puig Domingo, Manuel
    Davies, Melanie
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) : 880 - 886
  • [30] The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec plus insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial
    Mu, Yiming
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5497 - 5499
12345